Is a papular rash over the cheek in an adult patient with chronic kidney disease (CKD) stage 3, taking allopurinol (xanthine oxidase inhibitor) for many years, a side effect of the medication?

Is the Papular Rash a Side Effect of Allopurinol?

Yes, the papular rash over the cheek is very likely a side effect of allopurinol and requires immediate discontinuation of the medication. 1

Understanding Allopurinol-Induced Skin Reactions

Allopurinol-induced skin rash is the most frequent adverse reaction to this medication, and treatment must be discontinued immediately if a rash develops. 1 The FDA drug label explicitly states that skin reactions can be severe and sometimes fatal. 1

Clinical Presentation in This Case

The 6-month duration of this papular rash is concerning for several reasons:

• Maculopapular rashes are the most common cutaneous manifestation of allopurinol hypersensitivity, occurring in 79-82% of cases 2, 3
• The presence of CKD stage 3 significantly increases risk, with 86% of patients with allopurinol hypersensitivity syndrome having baseline renal impairment 3
• Chronic kidney disease stages 3,4, and 5 are strongly associated with severe cutaneous adverse reactions (adjusted hazard ratio 2.24 for stage 3,6.65 for stage 4,18.85 for stage 5) 4

Risk Factors Present in This Patient

This patient has multiple high-risk features:

• CKD stage 3 increases the incidence of skin rash 1
• 36% of patients who developed allopurinol hypersensitivity syndrome had pre-existing renal impairment 2
• Long-term use does not eliminate risk—reactions can occur after years of therapy 1

Immediate Management Steps

1. Stop Allopurinol Immediately

Discontinue allopurinol at the first sign of rash or other signs suggesting hypersensitivity reaction. 1 The FDA label is unequivocal: treatment should be discontinued immediately if a rash develops. 1

• Never continue the medication despite a rash, as this can progress to life-threatening conditions 5
• Avoid future use of allopurinol in patients who have experienced hypersensitivity reactions 1

2. Assess for Systemic Involvement

Examine for features of allopurinol hypersensitivity syndrome (AHS) or DRESS syndrome:

• Fever, eosinophilia (>20% eosinophils), elevated liver enzymes (hepatitis), and worsening renal function are characteristic features 6, 1
• Check complete blood count with differential, liver function tests, and renal function 7, 2
• AHS has a devastating 25% mortality rate and can manifest as Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS 6, 8
• Symptoms may develop approximately 1 week from initiating therapy, but longer latency periods occur 1

3. Initiate Supportive Treatment

Treatment of allopurinol hypersensitivity syndrome is primarily supportive. 6

• Systemic corticosteroids may be considered to control inflammatory manifestations 6, 7
• Monitor closely for progression to severe cutaneous adverse reactions 3
• The mortality rate for allopurinol hypersensitivity syndrome is 18% 3

Alternative Urate-Lowering Therapy

Switch to Febuxostat

For patients with CKD stage ≥3 who cannot tolerate allopurinol, febuxostat is the preferred alternative xanthine oxidase inhibitor. 9, 10

• Start febuxostat at ≤40 mg/day with subsequent dose titration 9, 10
• Xanthine oxidase inhibitors are strongly recommended over probenecid for CKD stage ≥3 9, 10

Important Considerations

• Do not attempt allopurinol desensitization in patients who have experienced hypersensitivity reactions 1
• If febuxostat is not tolerated or contraindicated, consider probenecid (though less preferred in CKD) or pegloticase for refractory cases 9, 10

Prevention Lessons for Future Prescribing

This case highlights critical prescribing errors:

• Allopurinol should be started at ≤100 mg/day (and even lower at ≤50 mg/day in CKD stage ≥3) with gradual titration every 2-5 weeks 10, 6
• HLA-B*58:01 testing should be considered before initiating allopurinol in high-risk populations, including Korean patients with CKD stage ≥3 and Han Chinese or Thai patients 6, 8
• Patients must be educated to report any rash immediately 8

Common Pitfalls to Avoid

• Never dismiss a rash as "minor" or "unrelated" in patients on allopurinol—the FDA label is explicit about immediate discontinuation 1
• Do not restart allopurinol after a hypersensitivity reaction, even at lower doses 1
• Recognize that long-term use does not confer immunity—reactions can occur after years of therapy 1
• Concomitant thiazide diuretic use increases risk (72% of patients with AHS were taking thiazides) 2